Biotech IV Monitor

NAMS — NewAmsterdam Pharma Company N.V.

$3.5B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for NewAmsterdam Pharma Company N.V., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is November 2027.

Next readoutNovember 2027in ~12 months
Upcoming readouts32 Phase 3
Market cap$3.5B
Cash & investments$643M~37 quarters at last loss rate

Upcoming readouts

Phase 3 obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Lipidemia; Coronary Artery Disease · NCT06305559
November 2027
Ongoing
Phase 3 obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Lipidemia; Type 2 Diabetes (T2DM) · NCT07219602
March 2028
Ongoing
Phase 2 Obicetrapib 10 mg
Preclinical Alzheimer's Disease · NCT07794670
September 2028
Recruiting

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 2 obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Dyslipidemias · NCT06496243
November 2026
Recruiting
Phase 3 Obicetrapib
Atherosclerotic Cardiovascular Disease · NCT05202509
November 2026
Ongoing

Cash position

NewAmsterdam Pharma Company N.V. reported $643M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $17M; at that rate the cash would last about 37 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Companies working on similar indications

Discussion

No messages yet. If you follow NAMS, you can start the conversation.
Track NAMS in real time
See live implied volatility for NAMS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on NAMS
Contact — questions or corrections about NAMS: dukeupt@gmail.com